Skip to main content
Taylor & Francis Group Logo
    Advanced Search

    Click here to search products using title name,author name and keywords.

    • Login
    • Hi, User  
      • Your Account
      • Logout
      Advanced Search

      Click here to search products using title name,author name and keywords.

      Breadcrumbs Section. Click here to navigate to respective pages.

      Chapter

      Drug Monitoring: Modern Approaches to Quality Assurance
      loading

      Chapter

      Drug Monitoring: Modern Approaches to Quality Assurance

      DOI link for Drug Monitoring: Modern Approaches to Quality Assurance

      Drug Monitoring: Modern Approaches to Quality Assurance book

      Drug Monitoring: Modern Approaches to Quality Assurance

      DOI link for Drug Monitoring: Modern Approaches to Quality Assurance

      Drug Monitoring: Modern Approaches to Quality Assurance book

      ByKaiser J. Aziz
      BookHandbook of Analytical Therapeutic Drug Monitoring and Toxicology

      Click here to navigate to parent product.

      Edition 1st Edition
      First Published 1997
      Imprint CRC Press
      Pages 15
      eBook ISBN 9780203713327
      Share
      Share

      ABSTRACT

      This chapter presents the US Food and Drug Administration (FDA) regulatory process as it relates to in vitro therapeutic drug monitoring devices. The increasing use of nonisotopic immunoassay systems is likely to have the greatest impact on standardization and total quality assurance of the system. To enable sponsors of new drugs to conduct the necessary studies, Congress permitted the FDA to exempt a drug from this prohibition and certain other requirements of the Act for the limited purpose of conducting clinical studies. In the US, FDA approval is required for a new drug for the indications specified in the New Drug Application. The FDA has, among its responsibilities, the regulation of medical devices. In the semantic framework of the FDA device evaluation process, a determination of whether a device is considered old or new is made based on whether it was in the commercial marketplace at the time of passage of the Medical Device Amendments of 1976.

      T&F logoTaylor & Francis Group logo
      • Policies
        • Privacy Policy
        • Terms & Conditions
        • Cookie Policy
        • Privacy Policy
        • Terms & Conditions
        • Cookie Policy
      • Journals
        • Taylor & Francis Online
        • CogentOA
        • Taylor & Francis Online
        • CogentOA
      • Corporate
        • Taylor & Francis Group
        • Taylor & Francis Group
        • Taylor & Francis Group
        • Taylor & Francis Group
      • Help & Contact
        • Students/Researchers
        • Librarians/Institutions
        • Students/Researchers
        • Librarians/Institutions
      • Connect with us

      Connect with us

      Registered in England & Wales No. 3099067
      5 Howick Place | London | SW1P 1WG © 2022 Informa UK Limited